Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pharma-Bio Serv (PBSV) Income from Continuing Operations (2016 - 2026)

Pharma-Bio Serv (PBSV) has disclosed Income from Continuing Operations for 15 consecutive years, with 102.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Income from Continuing Operations fell 100.63% year-over-year to 102.0, compared with a TTM value of 404497.0 through Oct 2025, up 47.98%, and an annual FY2025 reading of 100463.0, up 87.08% over the prior year.
  • Income from Continuing Operations was 102.0 for Q4 2025 at Pharma-Bio Serv, up from 309098.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 2275118.0 in Q3 2021 and bottomed at 4872661.0 in Q4 2021.
  • Average Income from Continuing Operations over 5 years is 49167.5, with a median of 123577.5 recorded in 2022.
  • Peak annual rise in Income from Continuing Operations hit 228.72% in 2021, while the deepest fall reached 3475.66% in 2021.
  • Year by year, Income from Continuing Operations stood at 4872661.0 in 2021, then surged by 104.74% to 231044.0 in 2022, then crashed by 122.11% to 51078.0 in 2023, then skyrocketed by 131.54% to 16111.0 in 2024, then plummeted by 100.63% to 102.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for PBSV at 102.0 in Q4 2025, 309098.0 in Q3 2025, and 103833.0 in Q2 2025.